| Literature DB >> 27855640 |
Constantinos Ergatoudes1, Erik Thunström1, Annika Rosengren1, Lena Björck1,2, Kristina Bengtsson Boström3, Kristin Falk2, Michael Fu4,5.
Abstract
BACKGROUND: A number of registry studies have reported suboptimal adherence to guidelines for cardiovascular prevention during the first year after acute myocardial infarction (AMI). However, only a few studies have addressed long-term secondary prevention after AMI. This study evaluates prevention guideline adherence and outcome of guideline-directed secondary prevention in patients surviving 2 years after AMI.Entities:
Keywords: Cardiovascular disease; Long-term; Myocardial infarction; Secondary prevention
Mesh:
Substances:
Year: 2016 PMID: 27855640 PMCID: PMC5114745 DOI: 10.1186/s12872-016-0400-6
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Secondary prevention guidelines after AMI
| 1 | Optimally controlled blood pressure, defined as SBP <140 mmHg |
| 2 | Optimally controlled cholesterol levels, defined as LDL cholesterol <1.8 mmol/L |
| 3 | Optimally controlled glucose, defined as HbA1c <48 mmol/mol |
| 4 | Regular physical activity that caused sweating at least two times a week |
| 5 | Smoking cessation, defined as non-smoking at the time of the interview |
| 6 | Pharmacological treatment with ACE inhibitors or ARBs |
AMI acute myocardial infarction, SBP systolic blood pressure, LDL low-density lipoprotein, ACE angiotensin-converting enzyme, ARB angiotensin II receptor blockers
Fig. 1Study flow chart
Social and clinical characteristics of patients at the time of the interview 2 years after AMI
| Groups | |||
|---|---|---|---|
| Variables | All | Men | Women |
| Age, years, mean ± SD | 65.5 ± 9.8 | 64.7 ± 9.5 | 68.2 ± 10.2 |
| Social factors | |||
| Born in Swedena
| 158 (79.3) | 123 (77.8) | 35 (83.3) |
| Higher educationa
| 47 (23.5) | 35 (22.2) | 12 (28.6) |
| Currently workinga
| 72 (34.4) | 62 (39.2) | 10 (23.8) |
| Smokinga
| |||
| Never (%) | 62 (31.0) | 45 (28.5) | 17 (40.5) |
| Regularly (%) | 13 (6.5) | 13 (8.2) | 0 (0.0) |
| Sometimes (%) | 12 (6.0) | 11 (7.0) | 1 (2.4) |
| Quit (%) | 113 (56.5) | 89 (56.3) | 24 (57.1) |
| Exercisea
| |||
| Sedentary n (%) | 28 (14) | 18 (11.4) | 10 (23.8) |
| Moderate activity n (%) | 81 (40.5) | 63 (39.9) | 18 (42.9) |
| Regular activity n, (%) | 50 (25.5) | 41 (35.9) | 9 (21.4) |
| Vigorous activity n, (%) | 41 (20.5) | 36 (22.8) | 5 (11.9) |
| Cardiovascular diseases | |||
| Atrial fibrillationa
| 29 (14.8) | 19 (12.3) | 10 (24.4) |
| Known heart failurea
| 16 (8.3) | 10 (6.5) | 6 (15.8) |
| Hypertensiona
| 123 (63.4) | 93 (61.2) | 30 (71.4) |
| Diabetesa
| 43 (21.8) | 37 (23.6) | 6 (15) |
| Stroke/TIAa
| 14 (7.2) | 12 (7.7) | 2 (4.9) |
| Hyperlipidemiaa
| 115 (63.9) | 90 (63.4) | 25 (65.8) |
| Previous MI | 26 (13.0) | 19 (12.0) | 8 (19.0) |
| Previous PCI | 23 (11.5) | 18 (11.4) | 5 (11.9) |
| Non-cardiovascular disease | |||
| Cancera
| 31 (15.5) | 22 (13.9) | 9 (21.4) |
| COPD | 39 (20.2) | 29 (19.1) | 10 (24.4) |
| OSA | 48 (29.6) | 37 (29.6) | 11 (29.7) |
| Renal failure GFR < 60 | 55 (27.5) | 33 (20.1) | 18 (42.9) |
| Renal failure GFR < 30 | 4 (2) | 4 (2.5) | 0 (0.0) |
| Depressed for at least 2 consecutive weeks in the past 12 monthsa
| 30 (15) | 20 (12.7) | 10 (23.8) |
Data were presented as n (%)
TIA transient ischemic attack, MI myocardial infarction, PCI percutaneous coronary intervention, COPD chronic obstructive pulmonary disease, OSA obstructive sleep apnea
aSelf-specified answers to questions in the SEPAT questionnaire
Physical examination and laboratory analysis at the time of the interview 2 years after the index AMI event
| Groups | |||
|---|---|---|---|
| All | Men | Women | |
| SBP (mmHg) | 137.5 (18) | 138.3 (18.3) | 134.2 (16.4) |
| DBP (mmHg) | 79.6 (10.3) | 80.7 (10.0) | 75.5 (10.5) |
| HR (beats/minute) | 59.7 (10.7) | 59.1 (10.8) | 61.9 (10.2) |
| Weight (Kg) | 84.7 (16.2) | 86.9 (15.4) | 76.4 (16.3) |
| BMI | |||
| 25 kg/m2 < BMI ≤30 kg/m2 (%) | 47.0 | 50.6 | 35.7 |
| > 30 kg/m2 (%) | 25.5 | 20.9 | 40.5 |
| Waist (cm) | 100.2 (12.4) | 101.4 (11.0) | 95.7 (16.1) |
| Lab | |||
| HbA1c (mmol/L) | 40.5 (9.3) | 39.8 (8.8) | 43.0 (10.5) |
| Cholesterol (mmol/L) | 4.1 (1.0) | 4.1 (0.9) | 4.5 (1.2) |
| LDL (mmol/L) | 2.4 (0.9) | 2.4 (0.8) | 2.6 (1.1) |
| HDL (mmol/L) | 1.4 (0.6) | 1.4 (0.4) | 1.6 (0.5) |
| ApoB/ApoA1 quote | 0.6 (0.2) | 0.6 (0.2) | 0.5 (0.2) |
| Triglycerides (mmol/L) | 1.3 (0.6) | 1.3 (0.6) | 1.3 (0.5) |
| P-glucose (mmol/L) | 5.7 (1.3) | 5.7 (1.3) | 5.7 (1.3) |
| NTproBNP (pg/ml) | 396.8 (750.7) | 344.1 (682.3) | 594.9 (949.6) |
| NTproBNP > 300 pg/ml (%) | 31.5 | 25.3 | 44.2 |
Data were presented as n (%), otherwise in mean (SD). SBP systolic blood pressure, DBP diastolic blood pressure, HR heart rate, BMI body mass index, LDL low density lipoprotein, HDL high density lipoprotein
Non-fatal cardiovascular events during the 2-year follow-up after the index AMI event
| Readmissions, all cause, | 101 (50.5) |
| Readmissions, cardiac, | 60 (30.0) |
| Recurrent myocardial infarction, | 16 (8.0) |
| Unstable angina, | 8 (4.0) |
| PCI, | 23 (11.5) |
| Cardiac surgery, | 19 (9.5) |
| Cardiac arrest, | 2 (1.0) |
| Stroke/TIA, | 9 (4.5) |
| Post-MI heart failure, | 40 (20.0) |
| Post-MI atrial fibrillation, | 15 (7.5) |
| Angina pectoris CCS ≥2, | 34 (17.0) |
AMI acute myocardial infarction, PCI percutaneous coronary intervention, TIA transient ischemic attack, MI myocardial infarction, CCS Canadian Cardiovascular Society
acardiac surgery: all surgical procedure related to heart except percutaneous coronary intervention
Development of a risk profile at the time of AMI and at the 2-year follow-up interview
| At AMI | At the 2-year follow-up interview | |
|---|---|---|
| No smoking | 155 (77.5) | 175 (87.5) |
| LDL cholesterol <1.8 mmol/L | 8 (4) | 37 (18.5) |
| HbA1C <4.8 mmol/mol | NA | 177 (88.5) |
| SBP <140 mmHg | 152 (76) | 114 (57) |
| Regular exercise training | NA | 90 (45.5) |
NA not available, AMI acute myocardial infarction, LDL low density lipoprotein, SBP systolic blood pressure
Comparison of pharmacological treatments at the time of the index AMI event and at interview 2 years after AMI
| At AMI | At interview | |
|---|---|---|
| Aspirin | 199 (99.5) | 183 (91.5) |
| Beta-blocker | 187 (93.5) | 166 (83.0) |
| ACE-inhibitor or Angiotensin receptor blocker | 177 (88.5) | 153 (76.5) |
| Statin | 193 (96.5) | 177 (88.5) |
| Clopidogrel/prasugrel | 179 (89.5) | 11 (5.5) |
AMI acute myocardial infarction, ACE angiotensin-converting enzyme
Fig. 2Number of achieved goals (%) of guideline standard secondary prevention two years post AMI